Angiotensin-converting enzyme inhibitors in essential hypertension

Alberto Zanchetti

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

At the Cambridge Conference, the pros and cons of various classes of antihypertensive drugs were extensively discussed, including the place of angiotensin-converting enzyme inhibitors in today's spectrum. A consensus was easily reached that the most important advantage of having the present broad armamentarium of antihypertensive drugs is that a wide choice is now available from which to find the most suitable agent for the individual patient. A revised stepped-care design was proposed, in which the doctor has the choice of starting antihypertensive therapy with a thiazide diuretic, a beta-blocker, an angiotensin-converting enzyme inhibitor, or a calcium antagonist. Small doses of any agent should be used to start with, and doses should not subsequently be increased beyond that at which side effects appear. Should such symptoms occur, the doctor has the choice of either switching to another first-step compound or reducing the dose of the first agent and combining it with one of other available drugs.

Original languageEnglish
Pages (from-to)S2-S5
JournalJournal of Cardiovascular Pharmacology
Volume9
Publication statusPublished - 1987

Fingerprint

Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Sodium Chloride Symporter Inhibitors
Proxy
Calcium
Pharmaceutical Preparations
Essential Hypertension
Therapeutics

Keywords

  • Angiotensin-converting enzyme inhibitors
  • Antihypertensive therapy
  • Beta-adrenergic blockers
  • Calcium antagonists
  • Diuretics
  • Stepped-care programs

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Angiotensin-converting enzyme inhibitors in essential hypertension. / Zanchetti, Alberto.

In: Journal of Cardiovascular Pharmacology, Vol. 9, 1987, p. S2-S5.

Research output: Contribution to journalArticle

@article{0152919a7977437fa6ffbf885af5e393,
title = "Angiotensin-converting enzyme inhibitors in essential hypertension",
abstract = "At the Cambridge Conference, the pros and cons of various classes of antihypertensive drugs were extensively discussed, including the place of angiotensin-converting enzyme inhibitors in today's spectrum. A consensus was easily reached that the most important advantage of having the present broad armamentarium of antihypertensive drugs is that a wide choice is now available from which to find the most suitable agent for the individual patient. A revised stepped-care design was proposed, in which the doctor has the choice of starting antihypertensive therapy with a thiazide diuretic, a beta-blocker, an angiotensin-converting enzyme inhibitor, or a calcium antagonist. Small doses of any agent should be used to start with, and doses should not subsequently be increased beyond that at which side effects appear. Should such symptoms occur, the doctor has the choice of either switching to another first-step compound or reducing the dose of the first agent and combining it with one of other available drugs.",
keywords = "Angiotensin-converting enzyme inhibitors, Antihypertensive therapy, Beta-adrenergic blockers, Calcium antagonists, Diuretics, Stepped-care programs",
author = "Alberto Zanchetti",
year = "1987",
language = "English",
volume = "9",
pages = "S2--S5",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Angiotensin-converting enzyme inhibitors in essential hypertension

AU - Zanchetti, Alberto

PY - 1987

Y1 - 1987

N2 - At the Cambridge Conference, the pros and cons of various classes of antihypertensive drugs were extensively discussed, including the place of angiotensin-converting enzyme inhibitors in today's spectrum. A consensus was easily reached that the most important advantage of having the present broad armamentarium of antihypertensive drugs is that a wide choice is now available from which to find the most suitable agent for the individual patient. A revised stepped-care design was proposed, in which the doctor has the choice of starting antihypertensive therapy with a thiazide diuretic, a beta-blocker, an angiotensin-converting enzyme inhibitor, or a calcium antagonist. Small doses of any agent should be used to start with, and doses should not subsequently be increased beyond that at which side effects appear. Should such symptoms occur, the doctor has the choice of either switching to another first-step compound or reducing the dose of the first agent and combining it with one of other available drugs.

AB - At the Cambridge Conference, the pros and cons of various classes of antihypertensive drugs were extensively discussed, including the place of angiotensin-converting enzyme inhibitors in today's spectrum. A consensus was easily reached that the most important advantage of having the present broad armamentarium of antihypertensive drugs is that a wide choice is now available from which to find the most suitable agent for the individual patient. A revised stepped-care design was proposed, in which the doctor has the choice of starting antihypertensive therapy with a thiazide diuretic, a beta-blocker, an angiotensin-converting enzyme inhibitor, or a calcium antagonist. Small doses of any agent should be used to start with, and doses should not subsequently be increased beyond that at which side effects appear. Should such symptoms occur, the doctor has the choice of either switching to another first-step compound or reducing the dose of the first agent and combining it with one of other available drugs.

KW - Angiotensin-converting enzyme inhibitors

KW - Antihypertensive therapy

KW - Beta-adrenergic blockers

KW - Calcium antagonists

KW - Diuretics

KW - Stepped-care programs

UR - http://www.scopus.com/inward/record.url?scp=0023202598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023202598&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - S2-S5

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

ER -